LTBi diagnosis, treatment and follow-up of TB contacts

All the variables included in the analysis can be found in this database. Variable labels include their descriptio

Figure 3

<p>Specificity of QuantiFERON-TB Gold In-Tube (A) and T.SPOT.TB (B), in HIV-infected patients with confirmed tuberculosis, stratified for tuberculosis burden setting. Pooled estimates derived from random effects (DerSimonian-Laird) modeling.</p

Figure 4

<p>Proportion of indeterminate results of QuantiFERON-TB Gold In-Tube (A) and T-SPOT.TB (B) in HIV-infected patients, stratified for tuberculosis burden setting. Pooled estimates derived from random effects (DerSimonian-Laird) modeling.</p

General and outcome-related characteristics of the 38 studies.

<p>IQR: interquartile range; n/N: number of studies with the condition/total number of studies;</p>*<p>Switzerland and sub-Saharan area.</p>**<p>Calculated from 17 studies enrolling HIV-uninfected individuals.</p>†<p>Data available for 34 studies;</p>‡<p>Only HIV-infected individuals.</p

Head-to-head comparison of sensitivity between IGRAs and TST in HIV-infected patients with culture-confirmed tuberculosis.

<p>IGRAs: Interferon-γ release assays; QFT-GIT: QuantiFERON®-TB Gold In-Tube; TST: Tuberculin skin test; n/N: positive cases/cases with active tuberculosis.</p>*<p>8 positive tests of 10 cases;</p>**<p>5 positive tests of 12 cases;</p>†<p>Indeterminate results of T-SPOT.TB excluded.</p

Proportion of indeterminate results of IGRAs in HIV-infected patients in four systematic reviews.

<p>NOTE: Stratification for high-burden and low-burden TB settings is roughly equivalent to low-income and high-income settings used by Cattamanchi <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0032482#pone.0032482-Cattamanchi1" target="_blank">[10]</a>, Metcalfe <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0032482#pone.0032482-Metcalfe1" target="_blank">[11]</a> and Chen <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0032482#pone.0032482-Chen1" target="_blank">[12]</a> in their systematic reviews; TB = tuberculosis; LTBI = latent tuberculosis infection; QFT-GIT = QuantiFERON Gold® In-Tube; N.D. = Not done.</p>*<p>Only patients screened for LTBI included;</p>†<p>Symptomatic patients, with and without active TB.</p

Flowchart for study selection.

<p>Flowchart for study selection.</p

Figure 2

<p>Sensitivity of QuantiFERON-TB Gold In-Tube (A) and T.SPOT.TB (B), in HIV-infected patients with confirmed tuberculosis, stratified for tuberculosis burden setting. Pooled estimates derived from random effects (DerSimonian-Laird) modeling.</p

Sensitivity and specificity of the IGRAs in HIV-infected patients in four systematic reviews.

<p>NOTE: Stratification for high-burden and low-burden TB settings is roughly equivalent to low-income and high-income settings used by Cattamanchi <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0032482#pone.0032482-Cattamanchi1" target="_blank">[10]</a>, Metcalfe <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0032482#pone.0032482-Metcalfe1" target="_blank">[11]</a> and Chen <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0032482#pone.0032482-Chen1" target="_blank">[12]</a> in their systematic reviews; TB = tuberculosis; QFT-GIT = QuantiFERON Gold® In-Tube; N.D. = Not done.</p>*<p>Sensitivity estimated by scoring indeterminate results negative;</p>†<p>Only one study;</p>‡<p>Two studies: 89% each respectively.</p

Head-to-head comparison of sensitivity between QFT-GIT and T-SPOT.TB in HIV-infected patients with culture-confirmed tuberculosis.

<p>QFT-GIT: QuantiFERON®-TB Gold In-Tube; n/N: positive cases/cases with active tuberculosis.</p